# Romiplostim

> Romiplostim is a thrombopoietin (TPO) receptor agonist engineered as a peptibody, combining peptide sequences that activate the TPO receptor with an antibody Fc fragment that extends its circulating half-life. It is approved for chronic immune thrombocytopenia (ITP) in adults and children who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. It is given as a once-weekly subcutaneous injection, typically administered and monitored by a healthcare professional based on regular platelet counts. It is a prescription-only biologic therapy requiring individualized, weight-based dosing.

- URL: https://www.lifeconverted.com/peptides/romiplostim
- Also known as: Nplate
- Primary category: Other & Clinical
- Effectiveness rank: #22 in Other & Clinical
- Evidence level: Well studied
- Route: Subcutaneous (Subcutaneous injection prepared and typically administered by a healthcare professional based on weekly platelet counts.)
- Dose range: 1-10 mcg
- Dose tiers: low 1 mcg; moderate 3 mcg; high 10 mcg
- Half-life: Highly variable between patients, generally reported in a range of about 1 to 34 days
- Timing: Weekly · clinician-directed
- Cycle: Continuous once-weekly dosing while platelet response is maintained, with dose titrated by 1 mcg/kg increments based on platelet counts on, Discontinued if no adequate platelet response is achieved after dose escalation to the maximum recommended dose over about four weeks off
- Storage: Refrigerate unopened vials at 2-8°C, protected from light; do not freeze; reconstituted solution should be used promptly or stored per product labeling.

## Mechanism of action

Romiplostim binds and activates the thrombopoietin receptor (MPL) on megakaryocytes and their progenitors, mimicking the action of endogenous thrombopoietin. This stimulates megakaryocyte proliferation and maturation, ultimately increasing platelet production and release from the bone marrow. Because it does not share sequence homology with native thrombopoietin, it was designed to avoid triggering antibodies that cross-react with the endogenous hormone.

## Reported benefits

- Increases and sustains platelet counts in chronic ITP resistant to first-line therapy
- Reduces the need for rescue therapies (corticosteroids, immunoglobulins) in responders
- Once-weekly dosing schedule
- Approved for use in both adults and children

## Reported side effects

- Headache, fatigue, and arthralgia
- Risk of thromboembolic events with excessive platelet elevation
- Bone marrow reticulin fibrosis with prolonged use, monitored periodically
- Worsening of thrombocytopenia after discontinuation (rebound) in some patients
- Increased risk of hematologic malignancy progression in patients with myelodysplastic syndromes (contraindicated in that population)

## Common protocols

- Weekly weight-based subcutaneous dosing for chronic immune thrombocytopenia in adults and children with an inadequate response to prior therapy

## Stacking notes

Used as monotherapy for chronic ITP in most regimens; sometimes combined with corticosteroids or other ITP therapies under hematology supervision.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer